Form 4: Vaxcyte COO Sells Shares Under 10b5-1 Plan

Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported the sale of 2,250 shares of common stock, totaling approximately $131,000, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., reported transactions involving the sale of common stock on April 1, 2026.
• A total of 2,250 shares were sold, with a weighted-average price of approximately $58.53 per share.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 9, 2025, which is designed to comply with affirmative defense conditions.
• Following these transactions, Wassil beneficially owns 162,994 shares of Vaxcyte common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the sale of shares by a key executive, even though it was conducted under a pre-defined plan.

Negatives

• The COO sold a significant number of shares, indicating a reduction in direct beneficial ownership.

Risks

• The sale of shares by a key executive could be perceived negatively by the market, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the actual sale of shares by management can sometimes be interpreted as a lack of confidence in near-term stock performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
• The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for executives managing personal finances or diversifying holdings. However, the volume and timing relative to company news can influence market perception.

Related Party Transactions

• Jim Wassil transferred 962 and 612 shares of Vaxcyte, Inc. Common Stock to his ex-spouse on March 25 and 26, 2026, respectively, pursuant to a divorce settlement agreement and a domestic relations order.

Stakeholder Impact

• Shareholders: May view the sale as a negative signal, potentially leading to short-term price pressure, despite the 10b5-1 plan.
• Employees: May be influenced by executive trading activity, though the 10b5-1 plan mitigates insider trading concerns.
• Management: Demonstrates adherence to a structured trading plan for personal financial management.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1 plan.
• The reporting person will provide detailed pricing information upon request.

Key Dates

Recommendation

The filing reports routine insider sales under a Rule 10b5-1 plan, which is a standard practice and does not inherently signal a change in the company's fundamental outlook. While insider selling can be a negative indicator, the pre-planned nature of these transactions reduces their predictive power. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments.

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Jim Wassil, Chief Operating Officer, Beneficial Ownership